You are here

Article Text

Article menu
Download PDFPDF
DTB drug review
▼Romosozumab for osteoporosis

Abstract

Generic name: Romosozumab

Brand name: Evenity

Formulation: 105 mg solution for injection in a pre-filled pen

Market Authorisation holder: UCB Pharma Limited

Indication: treatment of severe osteoporosis in postmenopausal women at high risk of fracture

Dose: 210 mg romosozumab (administered as two subcutaneous injections of 105 mg each) once a month for 12 months. It is recommended that patients begin antiresorptive therapy after completing treatment with romosozumab.

Cost: £427.75 for two pre-filled pens each containing 105 mg romosozumab

Classification: Prescription only medicine (POM) subject to additional monitoring (▼)

  • Bone Diseases
  • Health Care Quality
  • Access
  • and Evaluation

https://doi.org/10.1136/dtb.2021.000027

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Written by the DTB team; externally peer reviewed.